#Clinilabs is proud to have collaborated with eight researchers from leading academic medical centers in the US and Europe, Idorsia Pharmaceuticals Ltd, and Beacon Biosignals on the recent publication featured in SLEEP entitled: “Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder – A pooled post hoc analysis of two randomized Phase 3 clinical studies.”
Gary Zammit, PhD, President and CEO of Clinilabs Drug Development Corporation, commented: “Clinilabs was pleased to support the centralized PSG data management and scoring during Idorsia’s clinical development of daridorexant. After setting the standard in polysomnographic (PSG) data processing, we are now delighted to be actively engaged in the microstructure analysis of electroencephalographic (EEG) signals. Clinilabs is one of the few organizations worldwide where sponsors can collect EEG or quantitative EEG data in clinic and have data processed under one umbrella, by the same organization.”
The publication in SLEEP shows that daridorexant reduces neurophysiological signs of hyperarousal, which may help people with chronic insomnia fall asleep or transition into deeper stages of sleep. According to Dr. Zammit, “It is a pleasure to see such interesting data arise from the scientific collaboration between academia and industry.”
To read the complete article visit: Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder – A pooled post hoc analysis of two randomized Phase 3 clinical studies